Highlights in acute lymphoblastic leukemia (ALL) from ASH 2024 include significant results for blinatumomab in pediatric ALL, potential use of asciminib, and frontline use of CAR-T cell therapy.

2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

Chronic lymphocytic leukemia ... a high white blood cell or lymphocyte level. You’d get more tests to find out if this is leukemia. Two other types of leukemia -- acute myeloid leukemia ...

for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Approval was based on results from the ...

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...

CD37, a surface protein present on most acute myeloid leukemia (AML ... with normal hematopoietic stem cells, peripheral blood mononuclear cells, and AML cell lines. Analysis included ...

The CAR T-cells then recognise and attack the cancer cells. Some children and young people up the age of 25 years have a type of CAR T-cell therapy called tisagenlecleucel (Kymriah). It is for a type ...

Your child might have a stem cell transplant as part of their treatment for acute lymphoblastic leukaemia (ALL). Having a transplant means destroying as many leukaemia cells as possible and replacing ...

Marlise R. Luskin, MD, MSCE, speaks with Healio about findings from the phase 3 randomized Alliance A041501 trial.The study was put on hold due to grade 5 events among patients who received inotuzumab ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...